{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:38:22Z","timestamp":1772789902225,"version":"3.50.1"},"reference-count":87,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020975","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2342209","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T03:24:55Z","timestamp":1713842695000},"page":"682-696","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland"],"prefix":"10.1080","volume":"27","author":[{"given":"Michael F.","family":"M\u00f8rup","sequence":"first","affiliation":[{"name":"UCB Pharma","place":["Copenhagen, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Colombes, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damon","family":"Willems","sequence":"additional","affiliation":[{"name":"UCB Pharma Brussels","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Rose","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Slough, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Lyris","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Slough, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lamotte","sequence":"additional","affiliation":[{"name":"Th(is)Modeling","place":["Asse, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-0194","authenticated-orcid":false,"given":"Laetitia","family":"Gerlier","sequence":"additional","affiliation":[{"name":"IQVIA","place":["Zaventem, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Thom","sequence":"additional","affiliation":[{"name":"University of Bristol","place":["Bristol, UK"]},{"name":"Clifton Insight","place":["Bristol, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21621"},{"key":"e_1_3_3_3_1","unstructured":"National Axial Spondyloarthritis Society. Axial SpA (AS) facts and figures [Internet]. 2020 [cited 2020 May 31]. Available from: https:\/\/nass.co.uk\/about-as\/as-facts-and-figures\/"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00934-3"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000589"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208852"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105468"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1093-z"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02301-0"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-022-05073-7"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead598"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05642-6"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.09.002"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.10.009"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001108"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223937"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223528"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002663"},{"key":"e_1_3_3_20_1","unstructured":"NICE TA718. TA718 | Ixekizumab for treating axial spondyloarthritis | Guidance | NICE [Internet]. NICE; 2021 [cited 2022 Jan 12]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta718"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221111611"},{"key":"e_1_3_3_22_1","unstructured":"Medicines and Healthcare Products Regulatory Agency. MHRA products | Bimzelx [Internet]. 2023 [cited 2023 Nov 16]. Available from: https:\/\/products.mhra.gov.uk\/product\/?product=BIMZELX"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224803"},{"key":"e_1_3_3_24_1","unstructured":"Scottish Medicines Consortium. Bimekizumab (Bimzelx) SMC2616 [Internet]. Scottish Medicines Consortium; 2023 [cited 2024 Feb 26]. Available from: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/bimekizumab-bimzelx-axspa-abb-smc2616\/"},{"key":"e_1_3_3_25_1","unstructured":"NICE TA719. TA719 | Secukinumab for treating non-radiographic axial spondyloarthritis | guidance [Internet]. NICE; 2021 [cited 2022 Jan 12]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta719"},{"key":"e_1_3_3_26_1","unstructured":"Scottish Medicines Consortium. Ixekizumab (Taltz) SMC2440 [Internet]. Scottish Medicines Consortium; 2022 [cited 2023 Nov 14]. Available from: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/ixekizumab-taltz-full-smc2440\/"},{"key":"e_1_3_3_27_1","unstructured":"Scottish Medicines Consortium. Secukinumab (Cosentyx) SMC2308 [Internet]. Scottish Medicines Consortium; 2021 [cited 2023 Nov 14]. Available from: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/secukinumab-cosentyx-full-smc2308\/"},{"key":"e_1_3_3_28_1","unstructured":"Scottish Medicines Consortium. Secukinumab (Cosentyx) ID1159\/16 [Internet]. Scottish Medicines Consortium; 2016 [cited 2023 Nov 14]. Available from: https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/secukinumab-cosentyx-fullsubmission-115916\/"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39612"},{"key":"e_1_3_3_30_1","unstructured":"EMC Bimekizumab. Bimzelx 160\u2009mg solution for injection in pre-filled pen - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Aug 9]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/12834\/smpc"},{"key":"e_1_3_3_31_1","unstructured":"EMC Secukinumab. Cosentyx 150\u2009mg solution for injection in pre-filled pen - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Aug 9]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3669"},{"key":"e_1_3_3_32_1","unstructured":"EMC ixekizumab. Taltz 80\u2009mg solution for injection in pre-filled pen - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Aug 9]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/8199\/smpc"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.4001"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219585"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213474"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001280"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040758"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0108-4"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016717"},{"key":"e_1_3_3_40_1","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index","volume":"21","author":"Calin A","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, et\u00a0al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol. 1994;21:2281\u20132285.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"e_1_3_3_42_1","unstructured":"National Health Service. NHS England\u202f\u00bb national cost collection for the NHS [Internet]; 2022 [cited 2023 Nov 16]. Available from: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/"},{"key":"e_1_3_3_43_1","unstructured":"PSSRU. Unit costs of health and social care programme (2022 \u2013 2027) | the new home for the unit costs of health and social care report [Internet]; 2022 [cited 2023 Aug 9]. Available from: https:\/\/www.pssru.ac.uk\/unitcostsreport\/"},{"key":"e_1_3_3_44_1","unstructured":"British National Formulary. MedicinesComplete\u2014log in [Internet]; 2022 [cited 2023 Aug 9]. Available from: https:\/\/www.medicinescomplete.com\/log-in\/#\/browse\/bnf"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta20090"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.10.1219"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1539400"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S192235"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2023.2243081"},{"key":"e_1_3_3_50_1","unstructured":"NICE. TA407 | Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | guidance | NICE [Internet]. NICE; 2016 [cited 2022 Jan 12]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta407"},{"key":"e_1_3_3_51_1","unstructured":"Office for National Statistics. National life tables - life expectancy in the UK: 2018 to 2020 - Office for National Statistics [Internet]; 2020 [cited 2023 Nov 16]. Available from: https:\/\/www.ons.gov.uk\/releases\/nationallifetableslifeexpectancyintheuk2018to2020"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:BGEN.0000031153.63563.58"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151191"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0337-0"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42282"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1278"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.209"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203927"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091793"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204055"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001955"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150037"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa353"},{"key":"e_1_3_3_64_1","unstructured":"Yeh S-T. Using trapezoidal rule for the area under a curve calculation. SUGI 27 Proceedings Paper 229-27 April 2002."},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0697-3"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-021-00700-1"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13487257"},{"key":"e_1_3_3_68_1","unstructured":"Scottish Medicines Consortium. Ixekizumab 80mg solution for injection in pre-filled syringe or pen (Taltz\u00ae). SMC2440 June 2022."},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0675-9"},{"key":"e_1_3_3_70_1","unstructured":"Dubreuil M Walsh JA Deodhar A et\u00a0al. Real-world use of biologic disease-modifying anti\u2011rheumatic drugs in US patients with ankylosing spondylitis: persistence factors associated with discontinuation and dosing patterns. ISPOR | International Society for Pharmacoeconomics and Outcomes Research [Internet]; 2023 [cited 2024 Feb 6]. Available from: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/intl2023-3668\/125411"},{"issue":"12","key":"e_1_3_3_71_1","article-title":"Real-world usage of biologic disease-Modifying anti-Rheumatic drugs in patients with axial spondyloarthritis in Germany","volume":"26","author":"Anjohrin S","year":"2023","unstructured":"Anjohrin S, Song J, Ab\u00e9 C, et\u00a0al. Real-world usage of biologic disease-Modifying anti-Rheumatic drugs in patients with axial spondyloarthritis in Germany. Value Health [Internet]; 2023;26(12):S300; [cited 2023 Dec 18]. Available from: https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/euro2023-3785\/131124","journal-title":"Value Health [Internet]"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1156557"},{"key":"e_1_3_3_73_1","first-page":"S-158","article-title":"Nor-DMARD data management: implementation of data capture from electronic health records","volume":"32","author":"Olsen IC","year":"2014","unstructured":"Olsen IC, Haavardsholm EA, Moholt E, et\u00a0al. Nor-DMARD data management: implementation of data capture from electronic health records. Clin Exp Rheumatol. 2014;32:S-158\u2013S-162.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex457"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201933"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216746"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2012.02727.x"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224434"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02288-8"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24523"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.3807023818109"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213184"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41477"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32971-X"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1033"},{"key":"e_1_3_3_88_1","unstructured":"Xue Y Hu J Liu D et\u00a0al. Efficacy and safety of ixekizumab in Chinese patients with radiographic axial spondyloarthritis: 16-week results from a phase 3 study. ACR meeting abstracts [Internet]; 2022 [cited 2024 Jan 31]. Available from: https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-ixekizumab-in-chinese-patients-with-radiographic-axial-spondyloarthritis-16-week-results-from-a-phase-3-study\/"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2342209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:46:14Z","timestamp":1772779574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2342209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":87,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2342209"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2342209","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}